AIDS Vol. 25; No. 17: P. F21-F27 (11.13.11) - Monday, January
The seroprevalence of sexually transmitted HCV among men who
have sex with men in Amsterdam is stabilizing, recent data
show. Little is known, however, about the incidence of HCV re-
infection in MSM who have cleared HCV. In the current study,
the team assessed the incidence of HCV re-infection in HIV-
positive MSM who were HCV RNA-negative following HCV treatment
of acute primary infection.
The subjects of the Amsterdam-based study were HIV-infected
MSM attending two large outpatient clinics; the men were
previously diagnosed with a sexually transmitted acute HCV
infection and tested HCV RNA-negative at the conclusion of
treatment. "We defined HCV re-infection as detectable HCV RNA
in individuals with an undetectable HCV RNA at the end of
treatment accompanied by a switch in HCV genotype or clade,"
the authors wrote. Re-infection incidence was calculated using
Included in the analysis were 56 persons who became HCV RNA-
negative during primary acute HCV treatment. Five of these
cases relapsed and were not analyzed; 11 participants were re-
infected. HCV re-infection incidence in this group was 15.2
per 100 person-years (95 percent confidence interval 8.0-
26.5). Cumulative incidence within two years was 33 percent.
"An alarmingly high incidence of HCV re-infection was found in
this group," the authors concluded. "This high re-infection
rate indicates that current prevention measures should be
discussed, frequent HCV RNA testing should be continued after
successful treatment and, in case of possible relapse, clade
typing should be performed to exclude re-infection."